Catalyst
Slingshot members are tracking this event:
Amicus Therapeutics (FOLD) to complete Phase 3 study of Migalastat (AT1001-041) in patients with Fabry Disease in July 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| FOLD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 10, 2016
Occurred Source:
http://ir.amicusrx.com/releasedetail.cfm?ReleaseID=984007
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Migalastat, At1001-041, Fabry Disease, Open-label
